June 10, 2014 in Nation/World

Study tests drug’s ability to thwart Alzheimer’s

Experimental treatment used on healthy seniors
Associated Press
 

WASHINGTON – In one of the more ambitious attempts yet to thwart Alzheimer’s disease, a major study got underway Monday to see if an experimental drug can protect healthy seniors whose brains harbor silent signs that they’re at risk.

Scientists plan to eventually scan the brains of thousands of older volunteers in the U.S., Canada and Australia to find those with a sticky buildup believed to play a key role in development of Alzheimer’s – the first time so many people without memory problems get the chance to learn the potentially troubling news.

Having lots of that gunky protein called beta-amyloid doesn’t guarantee someone will get sick. But the big question: Could intervening so early make a difference for those who do?

“We have to get them at the stage when we can save their brains,” said Dr. Reisa Sperling of Boston’s Brigham and Women’s Hospital and Harvard Medical School, who is leading the effort.

Researchers are beginning to recruit volunteers, and on Monday a Rhode Island man became the first treated when he was hooked up for an IV infusion at Butler Hospital in Providence.

Peter Bristol, 70, figured he was at risk because his mother died of Alzheimer’s and his brother has it.

“I felt I needed to be proactive in seeking whatever therapies might be available for myself in the coming years,” said Bristol, who said he was prepared when a PET scan of his brain showed he harbored enough amyloid to qualify for the research.

He won’t know until the end of the so-called A4 Study – it stands for Anti-Amyloid Treatment in Asymptomatic Alzheimer’s – whether he received monthly infusions of the experimental medicine, Eli Lilly & Co.’s solanezumab, or a dummy drug.

Solanezumab is designed to help catch amyloid before it builds into the brain plaques that are a hallmark of Alzheimer’s. It failed in earlier studies to treat full-blown Alzheimer’s – but it did appear to help slow mental decline in patients with mild disease, raising interest in testing it even earlier.

Scientists now think Alzheimer’s begins ravaging the brain at least a decade before memory problems appear. Many believe the best chance of preventing or at least slowing the disease requires intervening, somehow, when people still appear healthy.

The $140 million study, funded by the National Institutes of Health, Lilly and others, will track if participants’ memory and amyloid levels change over three years.

© Copyright 2014 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


There is one comment on this story. Click here to view comment >>

Get stories like this in a free daily email